日前，人人乐披露公告称，公司预计2024年期末净资产修正后为-4.07亿元至-3.92亿元。此前，人人乐 的年报业绩预盈4.10亿元至4.60亿元。 触及两条退市条件 在上述业绩预告修正公告中，*ST人乐强调称，该公司或将触及两条退市条件而被深交所终止上市。首 先，由于预计2024年期末净资产修正后为-4.07亿元至-3.92亿元，这将触及《深圳证券交易所股票上市 规则》第9.3.12条第二项规定的退市情形；其次，根据年审会计师与审计委员会的沟通，会计师可能对 审计报告发表无法表示意见的非标准意见，这将触及《深圳证券交易所股票上市规则》第9.3.12条第三 项规定的退市情形。 当前，人人乐正深陷供应商诉讼的连锁危机。据公司公告，因多家供应商申请财产保全，公司及子公司 主要银行账号已被冻结，致使资金周转陷入瘫痪。天眼查数据还显示，人人乐目前涉及95起被执行人案 件，累计执行标的额高达7038.11万元。 此外，人人乐高层再添变数也为公司发展抹上一层阴影。2025年3月，上任仅一年半的董事长侯延奎突 然以健康为由请辞，卸去包括董事、董事长及法定代表人在内的所有职务。有消息称，这位具有实控 人"曲江系"背景的高管， ...

星标 ★ IPO日报 精彩文章第一时间推送 值得一提的是，公司已经连续两年财报被审计机构出具"无法表示意见"，触及财务类退市情形。 未来，上市委员会将作出是否终止公司股票上市的决定。 4月29日，公司股价再次跌停，收报0.62元。这已经是公司自3月28日起，在22个交易日内收获21个跌 停，也是公司连续10个交易日股价低于1元。 4月29日晚间，*ST鹏博（全称"鹏博士电信传媒集团股份有限公司"，600804.SH）发布公告称， 公司2024年度财务会计报告被中瑞诚会计师事务所出具无法表示意见的审计报告以及财务报告内部 控制被出具无法表示意见的审计报告，触及财务类退市指标情形，公司股票可能将被终止上市。公 司股票自2025年4月30日开市起停牌。 IPO日报发现，此后10个交易日*ST鹏博需要连续涨停，其股价才能回到1元以上。 制图： 佘诗婕 此外，公司本身还面临着面值退市风险。 双重退市风险 2024年5月，公司因2023年财报被审计机构出具"无法表示意见"，已于2024年被实施退市风险警示 （*ST）。根据《上海证券交易所股票上市规则》，如果*ST鹏博2024年度财务会计报告被出具保留意 见、无法表示意见 ...

Core Viewpoint - *ST Pengbo (Peng Doctor Telecom Media Group Co., Ltd.) faces potential delisting risks due to consecutive years of receiving "unable to express opinion" audit reports, with its stock possibly suspended from trading starting April 30, 2025 [1][2] Financial Performance - The company reported a net profit attributable to shareholders of approximately -88.47 million yuan for 2024, with total revenue around 187.67 million yuan [5] - *ST Pengbo has experienced a continuous decline in revenue for seven consecutive years from 2017 to 2023, with net profits of -1.17 billion yuan in 2021, -454 million yuan in 2022, and -93 million yuan in 2023 [5] - The company’s financial situation has deteriorated significantly, with a total loss exceeding 5 billion yuan in 2019 due to massive goodwill and fixed asset impairments [4] Operational Challenges - The company has been struggling with liquidity issues since 2019, exacerbated by price wars in the broadband industry and regulatory fee reductions [4] - *ST Pengbo has been involved in numerous lawsuits and arbitration cases, with some bank accounts frozen, indicating severe operational and financial risks [6] Regulatory Issues - The company is under investigation by the China Securities Regulatory Commission (CSRC) for alleged violations of information disclosure, including failure to disclose related party transactions and significant contracts [6][7] - The CSRC has imposed a fine of 10 million yuan on *ST Pengbo and a 15 million yuan fine on its actual controller, Yang Xueping, due to serious violations [6][7] Market Position - Once recognized as the "fourth largest operator" in China, *ST Pengbo has seen its market position decline significantly after divesting key assets like Changcheng Broadband [2][4] - The company primarily operates in data centers, cloud computing, and internet access services, but its transition efforts have not yielded expected results [2][5]

2025年4月，重庆惠程信息科技股份有限公司（以下简称"ST惠程"）发布2024年年度报告，报告期内， 公司多项关键财务指标出现较大变化，其中净利润同比下降7980.65%，经营活动产生的现金流量净额 同比下降515.87%，凸显公司面临的严峻形势。以下将对该公司年报进行详细解读。 营业收入：下滑22.40%，业务结构有变化 2024年，ST惠程实现营业收入197,235,872.29元，较上年的254,162,324.50元下降22.40%。从业务板块来 看，电力行业收入130,381,239.73元，占比66.10%，同比下降3.21%；新能源行业收入63,876,292.78元， 占比32.39%，同比下降24.90%；游戏行业收入归零，上年为27,734,934.67元，占比10.91% 。 公司表示，业绩下滑主要源于经营层面项目进展及完工进度不及预期，如光伏、风电项目；同时，市场 供求因素也导致充电桩业务执行订单减少。 扣非每股收益：亏损加深，达 -0.2159元 净利润：由盈转亏，降幅高达7980.65% 归属于上市公司股东的净利润为 -149,521,961.44元，而2023年为1,897,3 ...

Core Viewpoint - Nanguo Real Estate, a commercial real estate platform under China Power Construction Corporation, reported a significant increase in revenue but continued to face substantial losses, indicating a trend of "increased revenue without increased profit" [1] Financial Performance - In 2024, Nanguo Real Estate achieved an operating income of 2.97 billion yuan, a year-on-year increase of 180.46% [1] - The company's net profit after deducting non-recurring items was -2.774 billion yuan, a year-on-year decrease of 71.32%, maintaining a similar decline rate compared to 2023 [1] - As of the end of 2024, the net assets attributable to the parent company were -1.753 billion yuan, leading to a risk of delisting under new regulatory rules [1] Business Operations - Nanguo Real Estate operates 19 commercial projects with a total operational area of 1.16 million square meters and signed contracts with over 300 quality brands in the year [1] - In the urban operation sector, the company collaborates with local state-owned platforms, managing 12 projects with an operational area of 250,000 square meters, covering various asset types [1] Strategic Moves - Prior to the annual report, Nanguo Real Estate announced that China Power Construction Corporation plans to acquire the company's real estate development assets and liabilities, with specific transaction details yet to be determined [2] - This potential major asset restructuring could significantly alleviate the company's financial burden and optimize its asset structure, enhancing operational efficiency [3] Market Context - The ongoing liquidity crisis faced by Nanguo Real Estate has drawn attention, especially in light of recent regulatory policies aimed at stabilizing the real estate market [3] - The market remains in a weak recovery phase, and the sustainability of this recovery is uncertain, necessitating further observation [3]

当前正处于A股上市公司年报披露高峰期，记者注意到，中国注册会计师协会(以下简称"中注协")近一 段时间密集约谈会计师事务所，提示风险防范，提示内容包括可能触发股票退市条件的上市公司年报审 计风险、持续经营能力存在重大不确定性的上市公司年报审计风险等。 中注协表示，更严格的强制退市标准对审计工作提出更高要求，注册会计师要严守风险底线，审慎发表 审计意见，切实发挥执业监督作用，促进上市公司提升会计信息质量，维护社会公众利益。 同时，中注协还发出多项具体提示，包括"会计师事务所应将可能触发股票退市条件的上市公司审计项 目作为重点项目，委派具备丰富审计经验的项目组成员和项目质量复核人员，严格遵守独立性要求，强 化项目质量复核，确保所有重大事项和分歧事项解决之后再批准出具审计报告""项目组应结合退市风险 公司特点，保持应有的职业怀疑，加大反舞弊资源投入，增加审计程序的不可预见性，设计、实施有针 对性的反舞弊程序"等。 中注协4月27日公布的数据显示，截至2025年4月22日，54家事务所共为2560家上市公司出具了财务报表 审计报告。从审计报告意见类型看，2554家上市公司被出具了无保留意见审计报告(其中10家被出具带 ...

Core Viewpoint - Qinghai Spring (600381.SH) is facing a delisting risk due to financial indicators triggering delisting clauses, with a warning of "ST" (Special Treatment) to be implemented after the 2024 annual report disclosure [1][2]. Financial Performance - The company expects a net profit loss attributable to shareholders of between 187 million to 225 million yuan for 2024, with a revenue forecast of approximately 256 million to 285 million yuan [2]. - The revenue has been revised down from an initial forecast of 310 million to 339 million yuan to below 300 million yuan, which is critical as it is below the 300 million yuan threshold that could trigger delisting [3][4]. Audit and Regulatory Concerns - The initial financial forecast was questioned by the Shanghai Stock Exchange, leading to an inquiry regarding the authenticity of revenue and the nature of business income [4]. - The auditing firm has raised doubts about the credibility of Qinghai Spring's financial statements, indicating potential for a disclaimer or adverse opinion on the 2024 financial report if sufficient audit evidence cannot be obtained [4][5]. Sales and Revenue Issues - Concerns have been raised regarding the sales of Cordyceps, with reported sales of approximately 152 million yuan, but significant accounts receivable of 56.87 million yuan, suggesting issues with the sales model [5]. - The white liquor segment showed abnormal revenue growth in December, accounting for about 50% of annual sales, which is deemed lacking commercial rationale given the overall market conditions [6][7]. Customer Transactions and Revenue Recognition - The company has been scrutinized for recognizing sales revenue from customers who have not yet sold the products, raising questions about the legitimacy of reported sales figures [7][8]. - Specific customers, such as Chengdu Tinghua Ling, reported significant sales but had not achieved corresponding sales post-delivery, indicating potential revenue recognition issues [9][10]. Conclusion - The discrepancies in reported sales figures and the ongoing audit concerns suggest that the financial health of Qinghai Spring is under significant scrutiny, with the upcoming annual report expected to provide further clarity on these issues [12].

司尔特近日发布公告称无法在预定期限内披露2024年年度报告，这一事件的核心问题源于公司全资子公 司贵州路发实业有限公司的财务造假与管理人员职务侵占。 2． 股价暴跌压力：投资者情绪已受重创，公告发布后股价较2024年高点下跌约20%，且控股股东国购 产业质押的1.23亿股已跌破平仓线，可能引发爆仓连锁反应。 此次事件暴露了公司内控体系的重大缺陷。早在2024年，独立董事吴玉光、朱克亮就因"黄席利涉嫌职 务侵占"案件无法获得充分证据，对年报真实性提出质疑，但案件长期无进展，形成"挂案"，使得历史 财务数据的可信度持续受损。此次公告进一步证实，造假行为与职务犯罪直接相关，公司既是财务造假 的责任主体，也是内部人员侵占资金的受害者。 从市场影响看，司尔特面临多重风险： 1． 退市风险：根据深交所规则，若公司未能在法定期限（2025年4月30日）披露年报，股票将于5月4 日起停牌；停牌两个月后若仍无法披露，将被实施退市风险警示（*ST）；此后若再逾期两个月，可能 直接终止上市。 值得注意的是，公司此前发布的业绩预告显示2024年净利润同比增幅超100%，表面数据亮眼，但此次 事件揭示其业绩增长可能建立在虚假财务基础上 ...

此前，*ST恒立披露的《2024年度业绩预告》和《关于公司2024年年报编制及最新审计进展的公告》显示， 公司预计2024年度扣除非经常性损益后的净利润 为-4,300万元至-3,300万元，扣除后营业收入为30,000万元至35,000万元。关于部分营业收入确认，公司与年审会计师存在较大分歧，公司存在2024年营业收入低于 3亿元而被终止上市的风险。公司2024年度财务会计报告存在被出具非标准审计意见的风险，公司股票仍存在2024年年度报告披露后被终止上市的风险。 文/梧桐小新 近日，上海凯利泰医疗科技股份有限公司（凯利泰，300326）、恒立实业发展集团股份有限公司（*ST恒立，000622）、人人乐连锁商业集团股份有限公司（*ST 人乐，002336）三家公司宣布延期披露2024年年报。 1、凯利泰 披露的公告显示，根据目前定期报告编制工作进展情况，经公司管理层与审计师沟通， 双方在审计意见上存在较大分歧，且对于公司权益工具投资的 公允价值问题、关联方披露完整性、关联交易公允性审计机构仍需取得进一步的资料及执行相关审计程序。 公司将《2024年年度报告》、《2025年一季度报告》 及相关公告的披露时间 ...

Core Viewpoint - Unimed Pharmaceutical is facing its most severe survival test since its establishment due to significant production management deficiencies identified by the Tianjin Drug Administration, leading to a suspension of production and sales [1][3][5]. Financial Performance - Unimed's subsidiary, Tianjin Unimed, generated revenue of 217 million yuan in 2024, accounting for 60.09% of the company's total revenue, with interferon products contributing over 70% to this figure in the past three years [7][8]. - The company's total revenue for 2024 was approximately 360 million yuan, a decrease of 16.14% compared to 2023, with the interferon segment experiencing a 28.59% decline in revenue [8][10]. - The net loss for the company has been increasing, reaching 137 million yuan in 2024, with a significant quarterly loss of 167 million yuan in Q4 due to the suspension of core products [10][12]. Regulatory and Compliance Issues - This incident marks the second major quality issue for Tianjin Unimed in 2024, following a previous failure of the "human interferon α2b spray" to meet biological activity standards, resulting in procurement suspensions from several provinces [9][12]. - The company has faced continuous non-standard audit opinions for eight consecutive years, raising concerns about the fairness of drug pricing and ownership disputes of subsidiaries [9][12]. Market Reaction - Following the news of the production suspension, Unimed's stock price plummeted to 7.42 yuan per share, hitting the daily limit down, with a total market capitalization of approximately 4.895 billion yuan [3][10]. - The stock has been trading below 10 yuan since the second half of 2024, reflecting a nearly 90% decline from its peak in 2015 [10][12]. Future Outlook - The suspension of production has cut off the company's main cash flow and led to the urgent recall of inventory valued at 23.16 million yuan. If production does not resume within three months, the company may face ST (special treatment) status and potential delisting risks [12]. - The company is attempting to establish a special rectification team, but historical issues and a lack of market confidence complicate recovery efforts [12].